Theradig Creates Expert Committee For The MiCRA Project
News Oct 15, 2014
Theradig has created an experts committee for its miCRA project to support it with the development of its microRNA theranostics kit for rectal cancer. The miCRA project has received a start-up phase award by the French government's Worldwide Innovation Challenge.
For the first time, Theradiag has gathered a cross-disciplinary expert committee (clinical oncologists, gastroenterologists, surgeons, anatomical pathologist), all of whom are well-known specialists in treating rectal cancer. This panel will play a consultative role and be involved in continuing the study to identify circulating microRNA biomarkers for the development of a theranostics kit to predict the response to neoadjuvant therapy and metastatic relapse in locally advanced rectal cancer. Alongside clinical observations, this rapid and innovative test will provide a decision-making tool guiding the choice of therapeutic approach at an early stage on a personalized basis before any therapy.
"The creation of this committee of rectal cancer experts will help us to set in motion the biological validation phases for the biomarkers identified recently and patented at the initial stages of the miCRA project. Since it will provide access to retrospective and prospective cohort studies, this committee will help us to accelerate the validation of the microRNAs used to predict patient response to radiochemotherapy and metastatic relapse. This scientific and clinical support will also guide our efforts to confirm the positioning of our future product", comments Odile Prigneau, General Manager of Prestizia.
"This committee will advise the company and provide its medical expertise, which is critical for the validation of the miCRA project", adds Michel Finance, Chief Executive Officer of Theradiag. "In view of its frequency (fifth most common form of cancer in France) and its severity given its high rate of metastatic relapse, rectal cancer represents a major public health issue. Identifying predictive biomarkers would represent a valuable tool for selecting the most appropriate therapeutic strategy for each patient".